Vir Biotechnology (VIR) EBITDA Margin (2018 - 2026)
Vir Biotechnology (VIR) reported EBITDA Margin of 456172.41% for Q1 2026, down 45156994.0% on a YoY basis from N/an in Q1 2025, and down 609798.93% sequentially from 74.79% in Q4 2025.
Vir Biotechnology (VIR) EBITDA Margin (2018 - 2026) Analysis & Trends
Vir Biotechnology (VIR) has 9 years of EBITDA Margin data on file, last reported at 456172.41% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 45156994.0% year-over-year to 456172.41%; the trailing twelve-month figure through Mar 2026 stood at 720.14% (up 237958.0% YoY), and the FY2025 full-year result was 699.18%, up 9210.0% from the prior year.
- EBITDA Margin slipped to 456172.41% in Q1 2026, from 74.79% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 82.26% in Q1 2022 to a low of 456172.41% in Q1 2026.
- A 5-year average of 33727.91% and a median of 946.74% in 2024 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin surged 811025 bps in 2022 and tumbled 45156994 bps in 2026, its largest moves.
- Tracing VIR's EBITDA Margin over 5 years: stood at 304.6% in 2022, then tumbled by 172 bps to 828.12% in 2023, then retreated by 14 bps to 946.74% in 2024, then soared by 92 bps to 74.79% in 2025, then slumped by 609799 bps to 456172.41% in 2026.
- Business Quant data shows VIR's EBITDA Margin at 456172.41% in Q1 2026, 74.79% in Q4 2025, and 72267.92% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Vir Biotechnology | 1.28 Bn | 1.28 Bn | - | -456,172.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -456,172.41% |
| Dec 31, 2025 | -74.79% |
| Sep 30, 2025 | -72,267.92% |
| Jun 30, 2025 | -9,754.28% |
| Mar 31, 2025 | -4,602.47% |
| Dec 31, 2024 | -946.74% |
| Sep 30, 2024 | -9,718.66% |
| Jun 30, 2024 | -5,158.70% |
| Mar 31, 2024 | -154.90% |
| Dec 31, 2023 | -828.12% |
| Sep 30, 2023 | -7,075.86% |
| Jun 30, 2023 | -5,667.26% |
| Mar 31, 2023 | -227.73% |
| Dec 31, 2022 | -304.60% |
| Sep 30, 2022 | 52.05% |
| Jun 30, 2022 | -554.34% |
| Mar 31, 2022 | 82.26% |
| Dec 31, 2021 | 70.35% |
| Sep 30, 2021 | -51.52% |
| Jun 30, 2021 | 36.25% |